A Study of LY3437943 in Participants With Impaired and Normal Liver Function

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

43 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-07-13

Study Completion Date

2025-03-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to measure how much of LY3437943 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function compared to healthy participants with normal liver function. The safety and tolerability of LY3437943 will also be evaluated. The study may last up to 9 weeks for each participant including the screening period.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of LY3314814 in Participants With Liver Impairment

NCT03499041

Hepatic Impairment

WITHDRAWN PHASE1

A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment

NCT07165002

Healthy Hepatic Insufficiency

RECRUITING PHASE1

A Study of LY2216684 in Participants With Impaired Hepatic Function

NCT01241435

Depressive Disorder, Major

COMPLETED PHASE1

A Relative Bioavailability Study of LY3209590 in Healthy Participants

NCT05615532

Healthy

COMPLETED PHASE1

A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment

NCT01836185

Hepatic Insufficiency

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Hepatic Insufficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY3437943 (Normal Hepatic Function)

LY3437943 administered subcutaneously (SC).

Group Type EXPERIMENTAL

LY3437943

Intervention Type DRUG

Administered SC.

LY3437943 (Severe Hepatic Impairment)

LY3437943 administered SC.

Group Type EXPERIMENTAL

LY3437943

Intervention Type DRUG

Administered SC.

LY3437943 (Moderate Hepatic Impairment)

LY3437943 administered SC.

Group Type EXPERIMENTAL

LY3437943

Intervention Type DRUG

Administered SC.

LY3437943 (Mild Hepatic Impairment)

LY3437943 administered SC.

Group Type EXPERIMENTAL

LY3437943

Intervention Type DRUG

Administered SC.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY3437943

Administered SC.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

All Participants:

* Have a body mass index within the range 19.0 to 42.0 kilograms per meter squared (kg/m²), inclusive
* Healthy or various degrees of hepatic impairment depending on the study group

Exclusion Criteria

Participants with hepatic impairment:

* Have or are anticipating an organ transplant within the next 6 months
* Requires needle evacuation of ascites fluid more than 2 times per month
* Have had variceal bleeding within 3 months of check-in, unless the participant has undergone a successful banding procedure; in that case, may check-in from 1 month after the banding procedure

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes